Lymphomatoid Papulosis Type E With T-Cell Receptor Gamma Positivity
Issued Date
2025-01-01
Resource Type
eISSN
11787015
Scopus ID
2-s2.0-85216574216
Journal Title
Clinical, Cosmetic and Investigational Dermatology
Volume
18
Start Page
177
End Page
182
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical, Cosmetic and Investigational Dermatology Vol.18 (2025) , 177-182
Suggested Citation
Namasondhi A., Rutnin S., Jerasutus S., Boonsakan P., Triyangkulsri K. Lymphomatoid Papulosis Type E With T-Cell Receptor Gamma Positivity. Clinical, Cosmetic and Investigational Dermatology Vol.18 (2025) , 177-182. 182. doi:10.2147/CCID.S493027 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/104202
Title
Lymphomatoid Papulosis Type E With T-Cell Receptor Gamma Positivity
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Lymphomatoid papulosis (LyP) is currently categorized as a primary lymphoproliferative disorder that follows a chronic, recurrent clinical course. The diagnosis of LyP is mainly based on clinical presentation and histopathological correlation. Six subtypes of LyP have been described and recognized, each with different histological features and sometimes distinct clinical presentations. LyP type E is a subtype that histologically shows angioinvasion and angiodestruction by CD8 and CD30-positive pleomorphic T cells. Clinically, it usually presents with a few large necrotic nodules or ulcers on the trunk or extremities, unlike other subtypes of LyP. Despite an indolent clinical course, long-term follow-up is necessary due to the risk of developing concurrent or secondary lymphoma. In this report, we demonstrate a case of lymphomatoid papulosis type E presented with widespread small papulonecrotic eruptions, an atypical clinical manifestation, and an unusual immunohistochemical profile. The biopsy revealed CD8, CD30, CD56, and TCR-γ-positive atypical lymphocytic infiltration with angioinvasion and angiodestruction. The patient was successfully treated with low-dose methotrexate.